Ouabain, digitalis-like factors and hypertension

Journal of Hypertension

Volumn 10, Issue , 1992, Pages S99-S111

  Hamlyn, John M ^a   Manunta, Paolo ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

Blood pressure; Digoxin; Endogenous; Sodium potassium pump; Steroids

Indexed keywords

ADENOSINE TRIPHOSPHATASE (POTASSIUM SODIUM); DIGITALIS; OUABAIN;

CONFERENCE PAPER; ELECTROLYTE BALANCE; FLUID BALANCE; HUMAN; HYPERTENSION; NONHUMAN; PRESSOR RESPONSE; RAT;

ANIMAL; BLOOD PRESSURE; BLOOD PROTEINS; DIGITALIS GLYCOSIDES; HUMAN; HYPERTENSION; ION TRANSPORT; NA(+)-K(+)-EXCHANGING ATPASE; OUABAIN; SUPPORT, NON-U.S. GOV'T;

EID: 0027077508     PISSN: 02636352     EISSN: 14735598     Source Type: Journal    
DOI: 10.1097/00004872-199212000-00012     Document Type: Article

References (140)

1. Canfield VA, Xu K-Y, D’Aquila T, Shyjan AW, Levenson R: Molecular cloning of Na, K-ATPase alpha subunit from Hydra vulgaris. Soc Gen Physiol 1991, 46:231-236.
2. Baxter-Lowe LA, Guo JZ, Bergstrom EE, Hokin LE: Molecular cloning of the Na, K-ATPase alpha subunit in developing brine shrimp and sequence comparison with higher organisms. FEES Lett 1989, 257:181-187.
3. Swbadner KJ: Isozymes of the Na/K-ATPase. Biochim Biophys Acta 1989, 988:185-220.
4. Sverdlov Ed, Monastyrskaya Gs, Broude Ne, Ushkarev Ya, Alukmets Rl, Meukov Am, et al.: The family of human Na, K- ATPase genes: no less than five genes and/or pseudogenes related to the alpha subunit. FEBS Lett 1987, 217:275-278.
5. Shull GE, Greeb J, Lingrel JB: Molecular cloning of three distinct forms of the Na, K-ATPase alpha subunit from rat brain. Biochemistry 1986, 25:8125-8132.
6. Shull MM, Lingrel JB: Multiple genes encode the human Na, K-ATPase catalytic subunit. Proc Natl Acad Sci USA 1987, 84:4039-4043.
7. Takeyasu K, Lemas V, Fambrough DM: Stability of the Na, K- ATPase alpha subunit isoforms in evolution. Am J Physiol 1990, 28:C6l9-C630.
8. Repke KRH, Est M, Portius HJ: The cause of species variation in sensitivity to digitalis [in German]. Biochem Pharmacol 1965, 14:1785-1802.
9. Blanco G, Berberian G, Beauge L: Detection of a highly ouabain sensitive isoform of rat brainstem Na, K-ATPase. Biochim Biophys Acta 1990, 1027:1-7.
10. Siperstein MD, Murray AW, Titus E: Biosynthesis of cardiotonic steroids from cholesterol in the toad, Bufo marinus. Arch Biochem Biophys 1957, 67:154-160.
11. Lichtstein D, Kachalsky S, Deutsch J: Identification of a ouabain-like compound in toad skin and plasma as a bu- fodieneolide derivative. Life Sci 1986, 38:1261-1270.
12. Greeff K, Schadewaldt H: Introduction and remarks on the history of cardiac glycosides. In Cardiac Glycosides. Part I: Experimental Pharmacology. Edited by Greeff K. New York: Springer Verlag; 1981:1-12.
13. Horton JAG, Davison MHA Ouabain in the treatment of shock. Br J Anaesth 1955, 27:139-144.
14. Haddy FJ, Overbeck H: The role of humoral agents in volume expanded hypertension. Life Sci 1976, 19:935-948.
15. Blaustein MP: Sodium ions, calcium ions and blood pressure regulation and hypertension: an hypothesis. Am J Physiol 1977, 232:C165-C173.
16. Cappuccio FP, Markandu ND, Sagnella GA, MacGregor GA: The effect of oral digoxin on sodium excretion, renin-angiotensin-aldosterone system and blood pressure in normotensive subjects. Postgrad Med J 1986, 62:265-268.
17. Guthrie GP Jr: Effects of digoxin on responsiveness to the pressor actions of angiotensin and norepinephrine in man. J Clin Endocrinol Metah 1984, 68:76-80.
18. Kramer HJ, Glanzer K, Freitag T, Schonfeld J, Sorger M, Schlebusch H, et al.: Studies on the role of sodium and potassium activated adenosine triphosphatase inhibition in the pathogenesis of human hypertension. Klin Wochenschr 1984, 63:32-36.
19. Mason DT, Braunwald E: Studies on digitalis. X. Effects of ouabain on forearm vascular resistance and venous tone in normal subjects and in patients in heart failure. J Clin Invest 1964, 43:532-543.
20. Kumar R, Yankopoulos NA, Abelman WH: Ouabain-induced hypertension in a patient with decompensated hypertensive heart disease. Chest 1973, 63:105-107.
21. Smith TW, Haber E: Digitalis [second of four parts]. N Engl J Med 1973, 289:1010-1015.
22. Abaraquez RF: Digitalis in the treatment of hypertension, a preliminary report. Acta Med Philippina 1967, 3:161-170.
23. Overbeck HW: Elevated arterial pressure, vascular wall waterlogging and impaired cardiac growth in rats chronically receiving digoxin. Proc Soc Exp Biol Med 1981, 167:506-513.
24. Overbeck HW, Pamnani MB, Ku DD: Arterial wall waterlogging accompanying chronic digoxin treatment in dogs. Proc Soc Exp Biol Med 1980, 164:401-404.
25. Nirasawa Y, Temma K, Fink GD, Akera T: Inability of Na, K- ATPase inhibitor to cause hypertension in sodium-loaded or deoxycorticosterone-treated one kidney rats. Life Sci 1985, 37:767-774.
26. Spence CD, Coghlan JP, Whitworth JA, Scoggins BA: Digoxin administration enhances the pressor response to aldosterone administration in conscious sheep. Clin Exp Pharmacol Physiol 1989, 16:211-222.
27. Hilton P: Cellular sodium transport in essential hypertension. N Engl J Med 1986, 314:222-229.
28. Graves SW: Endogenous digitalis-like factors. CRC Crit Rev Clin Lab Sci 1986, 23:177-200.
29. Poston L: Endogenous sodium pump inhibitors: a role in essential hypertension? Clin Sci 1987, 72:647-655.
30. Kramer HJ, Meyer-Lehnert H, Michel H, Predel HG: Endogenous natriuretic and ouabain-like factors: their roles in body fluid volume and blood pressure regulation. Am J Hypertens 1991, 4:81-89.
31. Schoner W: Endogenous digitalis-like factors. Clin Exp Hypertens 1992, Al4:767-814.
32. Poston L, Sewell RB, Wilkinson SP, Richardson PJ, Wiluams R, Clarkson EM, et al.: Evidence for a circulating sodium transport inhibitor in essential hypertension. BMJ 1981, 282:847-849.
33. MacGregor GA, Fenton S, Alaghband-Zadeh J, Markandu ND, Roulston JE, deWardener HE: Evidence for a raised concentration of a circulating sodium transport inhibitor in essential hypertension. BMJ 1981, 283:1355-1357.
34. Edmonson RPS, MacGregor GA: Leucocyte cation transport in essential hypertension: its relationship to the renin angiotensin system. BMJ 1981, 282:1267-1269.
35. Moreth K, Renner D, Schoner W: A quantitative receptor assay for digitalis-like compounds in serum: demonstration of raised concentrations in essential hypertension and correlation with arterial pressure. Klin Wochenschr 1987, 65:179-184.
36. Kuske R, Moreth K, Renner D, Wizemann V, Schoner W: Sodium pump inhibitor in the serum of patients with essential hypertension and its partial purification from hemofiltrate. Klin Wochenschr 1987, 65 (suppl 8):53-59.
37. Kresinski JM, Godon JP, Rorive GL: Arguments for the presence of a Na. K-ATPase pump inhibitor in the plasma of uremic and essential hypertensive patients. Clin Exp Hypertens A7:721-733.
38. Pamnani MB, Burris JF, Jemionek JF, Huot SJ, Price M, Freis ED, et al.: Humoral Na-K pump inhibitor activity in essential hypertension and in normotensive subjects after acute volume expansion. Am J Hypertens 1989, 2:524-531.
39. Ashida T, Kuramochi M, Kojima S, Yoshimi H, Kawano Y, Kimura G, et al.: Effect of dietary sodium on the Na-K ATPase inhibitor in patients with essential hypertension. Am J Hypertens 1989, 2:560-562.
40. Forrester TE, Alleyne GAO: Sodium, potassium and rate constants for sodium efflux in leucocytes from hypertensive Jamaicans. BMJ 1981, 283:5-7.
41. Gudmundsson Andersson O, Herutz H, Jonsson O, Naucusr J, Wikstrand J, Berglund G: Blood pressure, intraerythrocyte content, and transmembrane flues of sodium during normal and high salt intake in subjects with and without a family history of hypertension: evidence against a sodium transport inhibitor. J Cardiovasc Pharmacol 1984, 6 (suppl I):S35-S4l.
42. Stokes GS, Monaghan JC, Middleton A, Gunn J, Marwood JF: Altered erythrocyte cation transport related to hypertension or oral contraception. Klin Wochenschr 1985, 63:42-44.
43. Moran T, Meyers J, Fitzgibbon W: Sodium intake, blood pressure and red cell sodium efflux. Clin Exp Hypertens 1981, A3:64l-653.
44. Edmonson RPS, Thomas RD, Hilton PJ, Patrick J, Jones NF: Abnormal leucocyte composition and sodium transport in essential hypertension. Lancet 1975, i:1003-1005.
45. Eisner DA, Smith TW: The Na, K pump and its effectors in cardiac muscle. In The Heart and Cardiovascular System. Edited by Fozzard H, Haber E, Jennings RB, Katz AM, Morgan HE. New York: Raven Press; 1992:863-902.
46. Hamlyn JM, Ashen MD, Forrest B, Rogowski AC, White RJ: Species sensitivity of the sodium pump to a circulating ouabain-like inhibitor in acute hypervolemia and DOCA hypertension: comparison with ouabain. Prog Biochem Pharmacol 1988, 23:22-34.
47. Hamlyn JM: Increased levels of a humoral digitalis-like factor in deoxycorticosterone acetate-induced hypertension in the pig. J Endocrinol 1989, 122:409-420.
48. Ringel R, Pinkas G, Hamlyn JM, Mullins L, Hamilton BP: Endogenous inhibition of red blood cell Na, K-ATPase in essential and pregnancy induced hypertension. Clin Exp Hypertens 1989, Al1:587-601.
49. Pamnani MB, Haddy FJ: Humoral sodium-potassium pump inhibitor in reduced renal mass-saline hypertensive rats. Prog Biochem Pharmacol 1988, 23:35-45.
50. Huot SJ, Pamnani MB, Clough DL, Buggy J, Bryant HJ, Harder DR, et al.: Sodium-potassium pump activity in reduced renal mass hypertension. Hypertension 1983, 5 (suppl I):I94-I100.
51. Brody MJ, Fink GD, Buggy J, Haywood JR, Gordon FJ, Johnson AK: The role of the anteroventral third ventricle (AV3V) region in experimental hypertension. Circ Res 1978, 43 (suppl I):I2-I13.
52. Songu-Mize E, Bealer SL, Caldwell RW: Effect of Av3V lesions on development of DOCA-salt hypertension and vascular Na-pump activity. Hypertension 1982, 4:575-580.
53. Hamlyn JM, Ringel R, Schaffer JS, Levinson PD, Hamilton BP, Kowarski AA, et al.: A circulating inhibitor of Na, K-ATPase associated with essential hypertension. Nature 1982, 300:650-652.
54. DeWardener HE, Fenton S, alaghband-Zadeh J, MacGregor GA: Raised concentration of a circulating Na, K-ATPase inhibitor in essential hypertension. Contrib Nephrol 1982, 30:185-191.
55. Kojima I, Yoshihara S, Ogata E: Involvement of endogenous digitalis-like substance in genesis of deoxycorticosterone- salt hypertension. Life Sci 1982, 30:1775-1781.
56. Devynck MA, Pernollet MG, Cloix JF, de The H, Kamal L, Elghozi JL, et al.: Circulating digitalis-like compounds in essential hypertension. Clin Exp Hypertens 1984, A6:44l-453.
57. Yamaji I, Kikuchi K, Nishimura M, Nozawa A, Hasagawa T, Kobayakawa H, et al.: The role of Na, K-ATPase inhibitor on pressor responsiveness in patients with benign essential hypertension. Am J Hypertens 1990, 3:176-181.
58. Umeda T, Naomi S, Inoue J, Ohno M, Miura F, Hamasaki S, et al.: Assay of a circulating sodium pump inhibitor in patients with essential hypertension and normotensive subjects. Clin Exp Hypertens 1987, A9:1209-1219.
59. Nishio I, Shima H, Tsuda K, Hano T, Masuyama Y: Relationship between the sympathetic nervous system and sodium potassium adenosine triphosphatase inhibitor in salt-sensitive patients with essential hypertension. J Hypertens 1988, 6 (suppl 4):S2l6-S218.
60. Shima H, Nishio I, Tsuda K, Yoshikawa H, Kimura K, Hano T, et al.: Relation of sodium-potassium adenosine triphosphatase inhibitor to sympathetic nervous system during salt-loading in essential hypertension. Jpn J Med 1989, 28:165-169.
61. Takahashi H, Matsusawa M, Okabayashi H, Suga K, Ikegaki I, Nishimura M, et al.: Endogenous ditalislike substance in an adult population in Japan. Am J Hypertens 1988, 1 (suppl 3):l68S-172S.
62. Goodlin RC: Antidigoxin antibodies in eclampsia. N Engl J Med 1988, 318:518-519.
63. Kunes J, Stolba P, Pohlova I, Jeunek J, Zicha J: The importance of endogenous digoxin-like factors in rats with various forms of experimental hypertension. Clin Exp Hypertens 1985, 7:707-720.
64. Huang CT, Smith RM: Lowering of blood pressure in chronic aortic coarctate hypertensive rats with digoxin antiserum. Life Sci 1984, 35:115-118.
65. Mann JFE, Miemitz R, Ganten U, Ritz E: Haemodynamic effects of intact digoxin antibody and its Fab fragments in experimental hypertension. J Hypertens 1987, 5:543-549.
66. Balzan S, Montali U, Biver P, Ghione S: Digoxin-binding antibodies reverse the effect of endogenous digitalis-like compounds on Na, K-ATPase in erythrocytes. J Hypertens 1991, 9 (suppl 6):S304-S305.
67. Gottlieb SS, Rogowski AC, Weinberg M, Krichten CM, Hamilton BP, Hamlyn JM: Elevated concentrations of endogenous ouabain in patients with congestive heart failure. Circulation 1992, 86:420-425.
68. Hamlyn JM: Endogenous digitalis: where are we? LSI Atlas Pharmacol 1988, 2:339-344.
69. Hamlyn JM, Blaustein MP, Bova S, DuCharme DW, Harris DW, Mandel F, et al.: Identification and characterization of a ouabain-like compound from human plasma. Proc Natl Acad Sci USA 1991, 88:6259-6263.
70. Hamlyn JM, Harris DW, Ludens JH: Digitalis-like activity in human plasma: purification, affinity and mechanism. J Biol Chem 1989, 264:7395-7404.
71. Hamlyn JM, Harris DW, Resau J, Ludens JH: Digitalis-like activity in human and bovine adrenals [abstract 171]. FASEB J 1990, 4:A295.
72. Ludens JH, Clark MA, Robinson FG, DuCharme DW: Rat adrenal cortex is a source of circulating ouabainlike compound. Hypertension 1992, 19:721-724.
73. Ludens JH, Clark MS, DuCharme DW, Harris DW, Lutzke BS, Mandel F, et al.: Purification of an endogenous ditalislike factor for structural analysis. Hypertension 1991, 17:923-929.
74. Bova S, Blaustein MP, Ludens JH, Harris DW, DuCharme DW, Hamlyn JM: Effects of an endogenous ouabainlike compound on heart and aorta. Hypertension 1991, 17:944-950.
75. Mathews WR, DuCharme DW, Hamlyn JM, Harris DW, Mandel F, Clark MA, et al.: Mass spectral characterization of an endogenous ditalislike factor from human plasma. Hypertension 1991, 17:930-935.
76. Hallaq HA, Haupert GT: Positive inotropic effects of the endogenous Na, K transporting ATPase inhibitor from the hypothalamus. Proc Natl Acad Sci USA 1989, 86:10080-10084.
77. Goto A, Ishiguro T, Yamada K, Ishii M, Yoshioka M, Eguchi C, et al.: Isolation of a urinary digitalis-like factor indistinguishable from digoxin. Biochem Biophys Res Commun 1990, 173:1093-1101.
78. Cloix J-F, Crabos M, Grichois MI, Meyer P: An endogenous digitalis-like compound extracted from human urine: biochemical and chemical properties. Can J Physiol Pharmacol 1987, 65:1522-1527.
79. Tamura M, Lam T-T, Inagami T: Isolation and characterization of a specific endogenous Na, K-ATPase inhibitor from bovine adrenal. Biochemistry 1988, 27:4244-4253.
80. Meyer K, Linde H: Collection of toad venoms and chemistry of the toad venom steroids. In Venomous Animals and Their Venoms, vol II, Venous Vertebrates. Edited by Bucherl W, Buckley EE. New York: Academic Press; 1971:521-556.
81. Smith TW, Haber E: Digitalis [third of four parts]. N Engl J Med 1973, 289:1063-1072.
82. Thomas DL, Quick MP, Morgan RP: Suspected foxglove (Dig italis purpurea) poisoning in a dairy cow. Vet Rec 1987, 120:300-301.
83. Harris DW, Clark MA, Fisher JF, Hamlyn JM, Kolbasa KP, Ludens JH, et al.: Development of an immunoassay for endogenous digitalis-like factor. Hypertension 1991, 17:936-943.
84. Sandor T, Idler DR: Steroid methodology. In Steroids in Nonmammalian Vertebrates. Edited by Idler DR. New York: Academic Press; 1972:6-36.
85. Malawista I, Davidson EA: Isolation and identification of rhamnose from rabbit skin. Nature 1961, 192:871-872.
86. Rosenfeld EL, Wiederschein GY: The metabolism of L-rhamnose in animal tissues. Bull Soc Chim Biol 1965, 47:1433-1440.
87. Bourrillon B, Michon J, Got R: Glycidic components in gonadotropin in serum from the pregnant mare [in French], Bull Soc Chim Biol 1959, 41:493-502.
88. Greeff K, Wirth KE: Pharmacokinetics of Strophanthus glycosides. In Cardiac Glycosides. Part II: Pharmacokinetics and Clinical Pharmacology. Edited by Greeff K. New York: Springer Verlag; 1981:57-85.
89. Selden R, Smith TW: Ouabain pharmacokinetics in dog and man: determination by radioimmunoassay. Circulation 1972, 45:1176-1182.
90. Manunta P, Hamilton BP, Rogowski AC, Pruce E, Hamlyn JM: Ouabain hypertensive rats (OHR): a new model of chronic hypertension [abstract P67]. J Hypertens 1992, 10 (suppl 4):S79.
91. Manunta P, Evans G, Hamilton BP, Gann D, Resau J, Hamlyn JM: A new syndrome with elevated plasma ouabain and hypertension secondary to an adrenocortical tumor [abstract P36], J Hypertens 1992, 10 (suppl 4):S27.
92. Manunta P, Ashen MD, Rogowski AC, Pinnaparpagua P, Hamilton BP, Hamlyn JM: Tissue distribution of ouabain in ouabain-hypertensive rats [abstract P99]. J Hypertens 1992, 10 (suppl 4):S128.
93. Boulanger BR, Lilly MP, Hamlyn JM, Shurtleff D, Gann DS: Adrenal secretion in the awake dog: effect of acute blood volume changes [abstract 1446]. FASEB J 1992, 6 (suppl 4):A1186.
94. Masugi F, Ogihara T, Hasegawa T, Tomii A Nagano M, Higashimori K, et al.: Circulating factor with ouabain-like immunoreactivity in patients with primary aldosteronism. Biochem Biophys Res Commun 1986, 135:41-45.
95. Masugi F, Ogihara T, Hasgawa T, Sakaguchi K, Kumahara Y: Normalization of high plasma levels of ouabain-like immunoreactivity in primary aldosteronism after removal of adrenals. J Hum Hypertens 1988, 2:409-420.
96. Laredo J, Hamlyn JM: Modulation of the release of Endogenous ouabain from human adrenal CRL 7050 cells by peptidergic and non-peptidergic secretagogues [abstract 79]. In Endocr Soc Abstracts, 74th Annual Meeting, San Antonio, Texas, June 24-27, 1992, p 71.
97. Pernollet MG, Au RM, Meyer P, Devynck M-A: Are the circulating digitalis-like compounds of adrenal origin? J Hypertens 1986, 4 (suppl 6):S382-S384.
98. Doris PA, Stocco DM: An endogenous digitalis-like factor from the adrenal gland: studies from adrenal tissue from various sources. Endocrinology 1989, 125:2573-2579.
99. Shaikh IM, Lau BWC, Siegfried BA, Valdes R: Isolation of digoxin-like immunoreactive factors from mammalian adrenal cortex. J Biol Chem 1991, 266:13672-13678.
100. Reichstein T: Cardenolides and pregnane glycosides [in German]. Naturwissenschaften 1967, 3:53-76.
101. Goto A, Yamada K, Ishii M, Sugimoto T: Digitalis-like activity in human plasma: relation to blood pressure and sodium balance. Am J Med 1990, 89:420-426.
102. Delva P, Capra C, Degan M, Minuz P, Covi G, Milan L, et al.: High plasma levels of a ouabain-like factor in normal pregnancy and in pre-eclampsia. Eur J Clin Invest 1989, 19:95-100.
103. Delva P, Degan M, Capra C, Fallo F, Mantero F, Menegazzi M, et al.: Plasma ouabain-like activity in essential hypertensive patients and in subjects with primary aldosteronism. Miner Electrolyte Metab 1989, 15:315-320.
104. Masugi F, Ogihara T, Hasegawa T, Kumahara Y: Ouabain and non-ouabain-like factors in plasma of patients with essential hypertension. Clin Exp Hypertens 1987, A9:1233-1242.
105. Goto A, Yamada K, Yagi N, Nagoshi H, Hui C, Sugimoto T: Novel concepts on the roles of ouabain-like compound (OLC) in hypertension [abstract P52], J Hypertens 1992, 10 (suppl 4):S50.
106. Masugi F, Ogihara T, Sakaguchi K, Tomii A, Hasegawa T, Chen Y, et al.: Partial purification and properties of a plasma ouabain-like inhibitor of Na, K-ATPase in patients with essential hypertension. J Hypertens 1988, 6 (suppl 4):S351-S353.
107. Manunta P, Rogowski AC, Hamilton BP, Hamlyn JM: Chronic reversible hypertension in rats induced by ouabain but not digoxin [abstract 30]. Hypertension 1992, 20:404.
108. Manunta P, Hamilton BP, Pruce E, Hamlyn JM: High dietary sodium raises plasma levels of ouabain in normal man [abstract P81]. J Hypertens 1992, 10 (suppl 4):S96.
109. Donner TW, Hamilton BP, Manunta P, Valente WA, Hamlyn JM: Plasma ouabain in patients with hyperthyroidism [abstract 312]. In Endocr Soc Abstracts, 74th Annual Meeting, San Antonio, Texas, June 24-27, 1992, p 129.
110. Hohl AS, Hamilton BP, Hamlyn JM: Dynamics of intracellular calcium, endogenous digitalis and other volume-sensitive hormones during 9-alpha fluorohydrocorticosterone administration to normal man [abstract 835]. Endocr Soc Abstracts, 72nd Annual Meeting, Atlanta, Georgia, June 20-23, 1990, p 233.
111. Schaeffer JS, Talartschik J, Koch KM, Rogowski AC, Manunta p, Hamlyn JM: Increased plasma levels of ouabainlike compound in dialysis patients: relationship with interdialytic volume changes [abstract 34P]. J Am Soc Nephrol 1991, 2:348.
112. Argento NB, Hamilton BP, Valente WA, Hamlyn JM: Increased circulating levels of a ouabain-like compound in hypothyroid hypertension [abstract PI 10]. Hypertension 1991, 18:425.
113. Kriegelstein J: Plasma protein binding of cardiac glycosides. In Cardiac Glycosides Part II: Pharmacokinetics and Clinical Pharmacology. Edited by Greeff K. New York: Springer Verlag; 1981:95-104.
114. Nakamura T, Hamlyn J, Granger JP: Renin-angiotensin aldosterone system and ouabain-like compound in dogs with obesity-induced hypertension [abstract]. Am f Hypertens 1991, 4:81A.
115. Chamberlain DA: The relationship of clinical effect to plasma digoxin concentration. Postgrad Med J 1974, 50:29-35.
116. Brown L, Erdmann E: Binding of digitalis derivatives to beef cat and human cardiac Na, K-ATPase: affinity and kinetic constants. Arch Int Pharmacodyn Ther 1984, 27:229-240.
117. Woolfson RG, Hilton PJ, Poston L: The effects of ouabain and low sodium on the contractility of human subcutaneous resistance vessels. Hypertension 1990, 15:583-590.
118. Woolfson RG, Poston L: Effect of ouabain on endothelium-dependent relaxation of human resistance arteries. Hypertension 1991, 17:691-625.
119. Yuan C, Manunta P, Chen S, Hamlyn JM, Pamnani MB: Hypertension induced by chronic ouabain administration in rats [abstract 48]. FASEB J 1992, 6:A495.
120. Lowenstein JM: A method for measuring plasma levels of digitalis glycosides. Circulation 1965, 3:228-233.
121. DeWardener HE, MacGregor GA: Dahl’s hypothesis that a saluretic substance may be responsible for a sustained rise in arterial pressure: its possible role in essential hypertension. Kidney Int 1980 18:1-9.
122. Adam-Vizi V, Ligeti E: Release of acetylcholine from rat synaptosomes by various agents in the absence of external calcium. J Physiol (Lond) 1984, 353:505-521.
123. Vizi ES, Oberfrank F, Bernath S, Lichstein D: Noradrenaline releasing effect of an ouabain-like compound on pulmonary artery. Neuropharmacology 1987, 26:1541-1544.
124. Powis DA: Cardiac glycosides and autonomic neurotransmission. J Autonom Pharmacol 1983, 3:127-154.
125. Tsuda K, Tsuda S, Shima H, Masuyama Y: Facilitatory effects of ouabain and digitalis-like substance on adrenergic transmission in hypertension. Am J Hypertens 1989, 2:465-467.
126. Taddei S, Salvetti A, Pedrinelu R: Ouabain vasoconstricts human forearm arterioles through alpha-adrenergic stimulation. J Hypertens 1988, 6 (suppl 4):S357-S359.
127. Garan H, Smith TW, Powell WJ Jr: Mechanism of vasoconstrictor effect of digoxin in coronary and skeletal muscle circulation [abstract]. Fed Proc 1973, 32:718.
128. Blaustein MP, Hamlyn JM: Pathogenesis of essential hypertension: a link between dietary salt and high blood pressure. Hypertension 1991, 18 (suppl III):III184-III195.
129. Lang S, Blaustein MP: The role of the sodium pump in the control of vascular tone. Circ Res 1980, 46:463-470.
130. Aalkjaert C, Mulvany MJ: Effect of ouabain on tone, membrane potential and sodium efflux compared with 3H- ouabain binding in rat resistance vessels. J Physiol 1985, 362:215-231.
131. Medford RM, Hyman R, Ahmad M, Allen JC, Pressley TA, Allen PD, et al.: Vascular smooth muscle expresses a truncated Na, K-ATPase alpha-1 subunit isoform. J Biol Chem 1991, 266:18308-18312.
132. Brender D, Vanhoutte PM, Shepherd JT: Potentiation of adrenergic venomotor responses in dogs by cardiac glycosides. Circ Res 1969, 25:597-606.
133. Henry M, Wehrien M, Pelletier B, Capron M-H: Spironolactone versus nifedipine in essential hypertension. Am J Cardiol 1990, 65:36K-38K.
134. Pamnani MB, Whitehorn WV, Clough DL, Haddy FJ: Effects of canrenone on blood pressure in rats with reduced renal mass. Am J Hypertens 1990, 3:188-195.
135. Vargas F, Haro JM, Jodar E, Soler E, Garcia del Rio C: Effects of K-canrenoate on the development of DOCA-salt hypertension. J Pharm Pharmacol 1988, 41:335-338.
136. Selye H, Krajny M, Savoie L: Digoxin poisoning: prevention by spironolactone. Science 1969, 164:842-843.
137. Finotti P, Palatini P: Canrenone as a partial agonist at the digitalis receptor site of sodium potassium activated adenosine triphosphatase. J Pharmacol Exp Tloer 1981, 217:784-790.
138. Yeh BK, Chaing BN, Sung PK: Antiarrythmic activity of K-canrenoate in man. Am Heart J 1976, 92:308-314.
139. Wirth KE, Froelich JC, Holufield JW, Falkner FC, Sweetman BS, Oates JA: Metabolism of digitoxin in man and its modification by spironolactone. Eur J Clin Pharmacol 1976, 9:345-354.
140. Garay RP, Dietz J, Hazare C, Dagher G, Abitbol JP: The interaction of canrenone with the Na +, K+ pump in human red blood cells. Naunyn Schmeidebergs Arch Pharmacol 1985, 329:311-315.